127 related articles for article (PubMed ID: 19215190)
1. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
Maniadakis N; Fragoulakis V; Pectasides D; Fountzilas G
Curr Med Res Opin; 2009 Mar; 25(3):797-805. PubMed ID: 19215190
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
[TBL] [Abstract][Full Text] [Related]
3. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Shiroiwa T; Fukuda T; Tsutani K
Br J Cancer; 2009 Jul; 101(1):12-8. PubMed ID: 19491895
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
[TBL] [Abstract][Full Text] [Related]
6. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
7. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Lapeyre-Prost A; Hug de Larauze M; Chibaudel B; Garcia ML; Guering-Meyer V; Bouché O; Boucher E; Ychou M; Dauba J; Obled S; Lièvre A; Malka D; Faroux R; Bonnet I; Taieb J; André T;
Clin Colorectal Cancer; 2016 Sep; 15(3):250-6. PubMed ID: 26752558
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
14. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Guo Y; Xiong BH; Zhang T; Cheng Y; Ma L
Cancer Invest; 2016; 34(2):94-104. PubMed ID: 26864862
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
16. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
17. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Brady J; Corrie P; Chau I; Digumarti R; Adams LM; Botbyl J; Laubscher KH; Midgley RS; Mallath M
Invest New Drugs; 2013 Oct; 31(5):1228-35. PubMed ID: 23456563
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Lu GC; Fang F; Li DC
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
